Thoracic Cancer (Feb 2024)
Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer
- Gen Lin,
- Zhijie Wang,
- Qian Chu,
- Yi Hu,
- Dingzhi Huang,
- Jun Wang,
- Fan Yang,
- Wenzhao Zhong,
- Chengzhi Zhou,
- Bo Zhu,
- Xinghao Ai,
- Baoshan Cao,
- Yabing Cao,
- Mingqiu Chen,
- Xiaohui Chen,
- Tianqing Chu,
- Jianchun Duan,
- Yun Fan,
- Yong Fang,
- Shuitu Feng,
- Weineng Feng,
- Hui Guo,
- Chengbo Han,
- Yong He,
- Shaodong Hong,
- Jie Hu,
- Meijuan Huang,
- Yan Huang,
- Da Jiang,
- Kan Jiang,
- Richeng Jiang,
- Bo Jin,
- Shi Jin,
- Jisheng Li,
- Min Li,
- Ziming Li,
- Chao Li,
- Jie Lin,
- Anwen Liu,
- Si‐Yang Maggie Liu,
- Liu Yutao,
- Zhefeng Liu,
- Zhe Liu,
- Zhenhua Liu,
- Zhentian Liu,
- Zhigang Liu,
- Yuping Lu,
- Tangfeng Lv,
- Zhiyong Ma,
- Qian Miao,
- Min Peng,
- Xingxiang Pu,
- Xiu Bao Ren,
- Jianzhen Shan,
- Jinlu Shan,
- Peng Shen,
- Bo Shen,
- Meiqi Shi,
- Yong Song,
- Zhengbo Song,
- ChunXia Su,
- Jianguo Sun,
- Panwen Tian,
- Jinliang Wang,
- Feng Wang,
- Huijuan Wang,
- Jialei Wang,
- Qian Wang,
- Wenxian Wang,
- Yan Wang,
- Lin Wu,
- Fang Wu,
- Yang Xia,
- Congying Xie,
- Conghua Xie,
- Tao Xin,
- Jianping Xiong,
- Haipeng Xu,
- Song Xu,
- Yiquan Xu,
- Bin Xu,
- Chunwei Xu,
- Xiaolong Yan,
- Zhenzhou Yang,
- Wenxiu Yao,
- Yao Yu,
- Ye Feng,
- Zongyang Yu,
- Yongfeng Yu,
- Dongsheng Yue,
- Haibo Zhang,
- HongMei Zhang,
- Li Zhang,
- Longfeng Zhang,
- Qiuyu Zhang,
- Tongmei Zhang,
- Bicheng Zhang,
- Jun Zhao,
- Mingfang Zhao,
- Xiaobin Zheng,
- Qiaofeng Zhong,
- Jin Zhou,
- Penghui Zhou,
- Zhengfei Zhu,
- Juntao Zou,
- Zihua Zou
Affiliations
- Gen Lin
- Department of Thoracic Oncology Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou China
- Zhijie Wang
- Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
- Qian Chu
- Department of Oncology, Tongji Hospital Tongji Medical College, Huazhong University of Science and Technology Wuhan China
- Yi Hu
- Senior Department of Oncology Chinese PLA General Hospital Beijing China
- Dingzhi Huang
- Department of Thoracic Oncology Tianjin Medical University Cancer Institute and Hospital Tianjin China
- Jun Wang
- Department of Oncology The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital Ji'nan China
- Fan Yang
- Department of Thoracic Surgery Peking University People's Hospital Beijing China
- Wenzhao Zhong
- Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences Guangzhou China
- Chengzhi Zhou
- Pulmonary and Critical Care Medicine, Guangzhou Institute of Respiratory Health, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, State Key Laboratory of Respiratory Diseases The First Affiliated Hospital of Guangzhou Medical University Guangzhou China
- Bo Zhu
- Institute of Cancer, Xinqiao Hospital Army Medical University Chongqing China
- Xinghao Ai
- Shanghai Lung Cancer Center, Shanghai Chest Hospital Shanghai Jiao Tong University School of Medicine Shanghai China
- Baoshan Cao
- Department of Medical Oncology and Radiation Sickness, Cancer Center Peking University Third Hospital Beijing China
- Yabing Cao
- Department of oncology Kiang Wu Hospital Macau China
- Mingqiu Chen
- Department of Thoracic Radiation Oncology Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou China
- Xiaohui Chen
- Department of Thoracic Surgery Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou China
- Tianqing Chu
- Respiratory Department, Shanghai Chest Hospital Shanghai Jiao Tong University School of Medicine Shanghai China
- Jianchun Duan
- Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
- Yun Fan
- Department of Medical Oncology Zhejiang Cancer Hospital Hangzhou China
- Yong Fang
- Department of Medical Oncology, Sir Run Run Shaw Hospital Zhenjiang University School of Medicine Hangzhou China
- Shuitu Feng
- Department of Medical Oncology Fudan University Shanghai Cancer Center Xiamen Hospital Xiamen China
- Weineng Feng
- Department of Pulmonary Oncology The First People's Hospital of Foshan Foshan China
- Hui Guo
- Department of Medical Oncology The First Affiliated Hospital of Xi'an Jiaotong University Xi'an China
- Chengbo Han
- Department of Oncology Shengjing Hospital of China Medical University Shenyang China
- Yong He
- Department of Respiratory Medicine, Xinqiao Hospital Army Medical University Chongqing China
- Shaodong Hong
- State Key Laboratory of Oncology in Southern China Sun Yat‐sen University Cancer Center Guangzhou China
- Jie Hu
- Shanghai Geriatric Center, Zhongshan Hospital Fudan University Shanghai China
- Meijuan Huang
- Division of Thoracic Tumor Multimodality Treatment and Department of Medical Oncology, Cancer Center, West China Hospital Sichuan University Chengdu China
- Yan Huang
- State Key Laboratory of Oncology in Southern China Sun Yat‐sen University Cancer Center Guangzhou China
- Da Jiang
- Department of Oncology The Fourth Affiliated Hospital of Hebei Medical University Shijiazhuang China
- Kan Jiang
- Department of Thoracic Oncology Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou China
- Richeng Jiang
- Department of Thoracic Oncology Tianjin Medical University Cancer Institute and Hospital Tianjin China
- Bo Jin
- Department of Medical Oncology The First affiliated hospital of China Medical University Shenyang China
- Shi Jin
- National Cancer Center/National Clinical Research Cencer for Cancer/Cancer Hospital &Shenzhen Hospital Chinese Academy of Medical Sciences and Perking Union Medical College Shenzhen China
- Jisheng Li
- Department of Medical Oncology Qilu Hospital of Shandong University Ji'nan China
- Min Li
- Department of Respiratory Medicine, Xiangya Hospital Central South University Changsha China
- Ziming Li
- Shanghai Lung Cancer Center, Shanghai Chest Hospital Shanghai Jiao Tong University School of Medicine Shanghai China
- Chao Li
- Department of Pathology Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou China
- Jie Lin
- Department of Medical Oncology The Second Affiliated Hospital of Kunming Medical University Kunming China
- Anwen Liu
- Department of Medical Oncology The Second Affiliated Hospital of Nanchang University Nanchang China
- Si‐Yang Maggie Liu
- Department of Hematology, First Affiliated Hospital Ji'nan University Guangzhou China
- Liu Yutao
- Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
- Zhefeng Liu
- Senior Department of Oncology Chinese PLA General Hospital Beijing China
- Zhe Liu
- Department of Medical Oncology, Beijing Chest Hospital Capital Medical University Beijing China
- Zhenhua Liu
- Department of Oncology Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital Fuzhou China
- Zhentian Liu
- Department of Thoracic Oncology Jiangxi Cancer Hospital Nanchang China
- Zhigang Liu
- Cancer Center The 10th Affiliated Hospital of Southern Medical University Dongguan China
- Yuping Lu
- Department of Abdominal Oncology Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou China
- Tangfeng Lv
- Department of Respiratory Medicine, Affiliated Jinling Hospital Medical School of Nanjing University Nanjing China
- Zhiyong Ma
- Department of Respiratory Medicine Henan cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University Zhengzhou China
- Qian Miao
- Department of Thoracic Oncology Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou China
- Min Peng
- Cancer cenrter Renmin Hospital of Wuhan University Wuhan China
- Xingxiang Pu
- Department of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China
- Xiu Bao Ren
- Department of Biotherapy Tianjin Medical University Cancer Institute and Hospital Tianjin China
- Jianzhen Shan
- Department of Medical Oncology The First Affiliated Hospital of Zhejiang University Zhejiang China
- Jinlu Shan
- Department of Medical Oncology, Daping Hospital Army Medical University Chongqing China
- Peng Shen
- Department of Oncology, Nanfang Hospital Southern Medical University Guangzhou China
- Bo Shen
- Department of Medical Oncology Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research and Affiliated Cancer Hospital of Nanjing Medical University Nanjing China
- Meiqi Shi
- Department of Medical Oncology Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research and Affiliated Cancer Hospital of Nanjing Medical University Nanjing China
- Yong Song
- Department of Respiratory Medicine, Affiliated Jinling Hospital Medical School of Nanjing University Nanjing China
- Zhengbo Song
- Department of Clinical Trial Zhejiang Cancer Hospital Hangzhou China
- ChunXia Su
- Department of Oncology Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine Shanghai China
- Jianguo Sun
- Institute of Cancer, Xinqiao Hospital Army Medical University Chongqing China
- Panwen Tian
- Precision Medicine Key Laboratory of Sichuan Province, Department of Pulmonary and Critical Care Medicine, Lung Cancer Center, West China Hospital Sichuan University Chengdu China
- Jinliang Wang
- Senior Department of Oncology Chinese PLA General Hospital Beijing China
- Feng Wang
- Department of Thoracic Surgery Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou China
- Huijuan Wang
- Department of Respiratory Medicine Henan cancer Hospital, Affiliated Cancer Hospital of Zhengzhou University Zhengzhou China
- Jialei Wang
- Department of Thoracic Medical Oncology Fudan University Shanghai Cancer Center Shanghai China
- Qian Wang
- Department of Respiratory Medicine Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine Nanjing China
- Wenxian Wang
- Department of Medical Oncology Zhejiang Cancer Hospital Hangzhou China
- Yan Wang
- Department of Medical Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
- Lin Wu
- Department of Thoracic Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University Changsha China
- Fang Wu
- Department of Oncology, The Second Xiangya Hospital Central South University Changsha China
- Yang Xia
- Department of Respiratory and Critical Care Medicine Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou China
- Congying Xie
- Department of Radiation and Medical Oncology Second Affiliated Hospital of Wenzhou Medical University Wenzhou China
- Conghua Xie
- Department of Pulmonary Oncology Zhongnan Hospital of Wuhan University Wuhan China
- Tao Xin
- Department of Oncology The Second Affiliated Hospital of Harbin Medical University Harbin China
- Jianping Xiong
- Department of Oncology The First Affiliated Hospital of Nanchang University Nanchang China
- Haipeng Xu
- Department of Thoracic Oncology Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou China
- Song Xu
- Department of Lung Cancer Surgery Tianjin Medical University General Hospital Tianjin China
- Yiquan Xu
- Department of Thoracic Oncology Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou China
- Bin Xu
- Cancer cenrter Renmin Hospital of Wuhan University Wuhan China
- Chunwei Xu
- Department of Respiratory Medicine, Affiliated Jinling Hospital Medical School of Nanjing University Nanjing China
- Xiaolong Yan
- Department of Thoracic Surgery, Tangdu Hospital Air Force Medical University Xi'an China
- Zhenzhou Yang
- Department of Cancer Center The Second Affiliated Hospital of Chongqing Medical University Chongqing China
- Wenxiu Yao
- Department of Medical Oncology, Sichuan Cancer Hospital University of Electronic Science and Technology of China Chengdu China
- Yao Yu
- Department of Medical Oncology The First Affiliated Hospital of Xi'an Jiaotong University Xi'an China
- Ye Feng
- Department of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University Xiamen China
- Zongyang Yu
- Department of Respiratory Medicine The 900th Hospital of the Joint Logistic Support Force, People's Liberation Army of China Fuzhou China
- Yongfeng Yu
- Shanghai Lung Cancer Center, Shanghai Chest Hospital Shanghai Jiao Tong University School of Medicine Shanghai China
- Dongsheng Yue
- Department of Lung Cancer Tianjin Medical University Cancer Institute and Hospital Tianjin China
- Haibo Zhang
- Department of Oncology Guangdong Provicial Hospital of Chinese Medicine Guangzhou China
- HongMei Zhang
- Department of Clinical Oncology, Xijing Hospital Air Force Medical University Xi'an China
- Li Zhang
- Department of Oncology, Tongji Hospital Tongji Medical College, Huazhong University of Science and Technology Wuhan China
- Longfeng Zhang
- Department of Thoracic Oncology Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou China
- Qiuyu Zhang
- Institute of Immunotherapy Fujian Medical University Fuzhou China
- Tongmei Zhang
- Department of Medical Oncology, Beijing Chest Hospital Capital Medical University Beijing China
- Bicheng Zhang
- Cancer cenrter Renmin Hospital of Wuhan University Wuhan China
- Jun Zhao
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department I of Thoracic Oncology Peking University Cancer Hospital and Institute Beijing China
- Mingfang Zhao
- Department of Medical Oncology The First affiliated hospital of China Medical University Shenyang China
- Xiaobin Zheng
- Department of Thoracic Oncology Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou China
- Qiaofeng Zhong
- Department of Thoracic Oncology Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou China
- Jin Zhou
- Department of Medical Oncology, Sichuan Cancer Hospital University of Electronic Science and Technology of China Chengdu China
- Penghui Zhou
- State Key Laboratory of Oncology in Southern China Sun Yat‐sen University Cancer Center Guangzhou China
- Zhengfei Zhu
- Department of Radiation Oncology Fudan University Shanghai Cancer Center Shanghai China
- Juntao Zou
- Department of Respiratory Medicine The First Affiliated Hospital of Nanchang University Nanchang China
- Zihua Zou
- Department of Thoracic Oncology Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital Fuzhou China
- DOI
- https://doi.org/10.1111/1759-7714.15209
- Journal volume & issue
-
Vol. 15,
no. 5
pp. 419 – 426
Abstract
Abstract Immune checkpoint inhibitor (ICI) rechallenge in non‐small cell lung cancer (NSCLC) is a promising therapeutic strategy. The situation for ICI rechallenge can be divided into three categories: adverse events (AEs); resistance to ICIs, and rechallenge becomes compulsive because of tumor relapse while the patients had completed a 2 year course of immunotherapy. However, these categories are still controversial and should be explored further. Through voting at the 6th Straits Summit Forum on Lung Cancer, in this study we summarize the consensus of 147 experts in ICI rechallenges. A total of 97.74% experts agreed to rechallenge; 48.87% experts rechallenge with the original drug, and the others rechallenge with a different drug; 40.3% agreed to rechallenge directly after progression; 88.06% experts agreed to ICI rechallenge with a combination regimen; and factors such as previous performance status score, PD‐1 expression, and age should also be considered. Understanding the the clinical studies in ICI rechallenge could bring us one step closer to understanding the consensus. In patients with advanced NSCLC who have suffered recurrent or distant metastasis after immunotherapy, the option of rechallenge with ICIs is a promising treatment option.
Keywords
